<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01597219</url>
  </required_header>
  <id_info>
    <org_study_id>UCL/10/0411</org_study_id>
    <nct_id>NCT01597219</nct_id>
  </id_info>
  <brief_title>Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers</brief_title>
  <acronym>UK-Haplo</acronym>
  <official_title>A UK Multicentre Study of Haploidentical Stem Cell Transplantation in Patients With Haematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bloodwise</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial investigates stem cell transplants from partially mismatched donors in patients
      with blood and bone marrow cancers. The trial will test two kinds of transplants - a full
      intensity transplant using a high dose of radiotherapy and chemotherapy, and a reduced
      intensity transplant with lower doses of chemotherapy and radiotherapy. Patients will be
      entered for the treatment pathway that is most appropriate for their level of health and
      fitness
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year post transplant</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Hodgkin's Lymphoma</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Acute Myeloid Leukaemia</condition>
  <condition>Acute Lymphoblastic Leukaemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Chronic Myeloid Leukaemia</condition>
  <condition>Chronic Lymphocytic Leukaemia</condition>
  <condition>Acquired Bone Marrow Failure Syndromes</condition>
  <condition>Other Haematological Malignancies; Unrelated HSCT Indicated</condition>
  <arm_group>
    <arm_group_label>Reduced intensity haploidentical transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine 30mg/m2 IV days -6 to -2 Cyclophosphamide 14.5 mg/kg IV days -6 and -5 Total body irradiation 2Gy day -1 Stem cell transplant: day 0 Cyclophosphamide 50mg/kg days +3 &amp; +4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Myeloablative haploidentical stem cell transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total body irradiation 12Gy in 8 fractions days -9 to -6 Donor lymphocyte infusion day -6 Cyclophosphamide 60mg/kg IV days -3 &amp; -2 Stem cell transplant day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Reduced intensity haplodentical stem cell transplant</intervention_name>
    <description>Fludarabine 30mg/m2 IV days -6 to -2 Cyclophosphamide 14.5 mg/kg IV days -6 and -5 Total body irradiation 2Gy day -1 Stem cell transplant: day 0 Cyclophosphamide 50mg/kg days +3 &amp; +4</description>
    <arm_group_label>Reduced intensity haploidentical transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Myeloablative haploidentical stem cell transplant</intervention_name>
    <description>Total body irradiation 12Gy in 8 fractions days -9 to -6 Donor lymphocyte infusion day -6 Cyclophosphamide 60mg/kg IV days -3 &amp; -2 Stem cell transplant day 0</description>
    <arm_group_label>Myeloablative haploidentical stem cell transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patient Inclusion Criteria

          1. Eligible for an allogeneic transplant in line with the current BSBMT indications for
             transplant criteria (http://bsbmt.org/indications-table/) accepted by Commissioners

          2. Age 16-70

          3. Adequate physical function

               -  Cardiac: LVEF at rest ≥45%, or shortening fraction ≥25%

               -  Hepatic: Bilirubin ≤35mmol/l; AST/ALT and alkaline phosphatase &lt;5 x ULN

               -  Renal: Serum creatinine within normal range for age, or if serum creatinine
                  outside normal range for age, creatinine clearance or GFR &gt;40ml/min/1.73m2

               -  Pulmonary: FEV1, FVC, DLCO (diffusion capacity) &gt;50% predicted (corrected for
                  haemoglobin); if clinically unable to perform pulmonary function tests then O2
                  saturation &gt;92% on room air

               -  Performance status: Karnofsky score ≥60%

          4. Donor available aged ≥16 years

          5. Needs an urgent transplant where a 10/10 HLA matched sibling or unrelated donor is
             unavailable in a timely manner. An unrelated donor search is not required for a
             patient to be eligible if the clinical situation dictates an urgent transplant.
             Clinical urgency is defined as 6-8 weeks from referral to transplant centre or low
             likelihood of finding a matched unrelated donor

          6. HLA typing will be performed at high resolution (allelic) for the HLA-A, HLA-B,
             HLA-Cw, HLA-DRB1 and HLA-DQB1 loci. A minimum match of 5/10 is required

          7. The donor and recipient must be identical as determined by high resolution typing at
             at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw,
             HLA-DRB1 and HLA-DQB1. Fulfilment of this criterion is sufficient evidence that the
             donor and recipient share one HLA haplotype and typing of additional family members is
             not required.

          8. Patient must have received cytotoxic chemotherapy within 3 months of the consent date
             (measured from the start date of the most recent cycle of chemotherapy) except
             patients with aplastic anaemia, unless otherwise agreed by the TMG (see section
             5.3.4). The use of monoclonal antibody therapy may be considered cytotoxic
             chemotherapy, but must be agreed by the TMG

          9. Written informed consent

        Donor Inclusion Criteria

          1. Donor must be an HLA-haploidentical first degree relative of the patient. Eligible
             donors include biological parents, siblings, children or half-siblings

          2. Age ≥16 years

          3. Donors must meet the collection centre's usual selection criteria for related
             allogeneic HPC donors

        Patient Exclusion Criteria

          1. HLA matched, related donor able to donate

          2. Autologous haematopoietic stem cell transplant &lt;3 months prior to enrolment

          3. Pregnancy or breastfeeding

          4. Uncontrolled bacterial, viral or fungal infection (currently taking medication with
             evidence of progression of clinical symptoms or radiological findings), the inclusion
             of patients with an uncontrolled viral or fungal infection can be agreed by the TMG

          5. Serious psychiatric or psychological disorders

          6. Absence or inability to provide informed consent

          7. Severe comorbidity (HCT-CI comorbidity score of 3 or more) or disease that prevents
             treatment with chemotherapy, unless otherwise agreed by the TMG

          8. Positive anti-donor HLA antibody

          9. Unable to receive 2Gy TBI (RIC pathway) or 12Gy TBI (MAC pathway)

         10. Patients with graft rejection following a previous allograft from either adult or cord
             blood donors

        Donor Exclusion Criteria

          1. Positive anti-donor HLA antibody in the recipient

          2. Pregnancy or recent birth (within 6 months prior to donating cells)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Kavita Raj</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College Hospital NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Husne Timur Tezver</last_name>
    <phone>+44(0)207 679 9860</phone>
    <email>ctc.uk-haplo@ucl.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Birmingham Heartlands</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Shankara Paneesha</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Infirmary</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Rachel Protheroe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Ben Uttenthal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beatson Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Dave Irvine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St James' University Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Maria Gilleece</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Rahuman Salim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Kavita Raj</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Panagiotis Kottaridis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Eleni Tholouli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prof Matthew Colin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire, Sheffield &amp; Weston Park</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prof John Snowden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2012</study_first_submitted>
  <study_first_submitted_qc>May 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2012</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haploidentical transplant</keyword>
  <keyword>Haematological malignancy</keyword>
  <keyword>Myeloablative</keyword>
  <keyword>Reduced intensity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

